Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

by dyadic | Feb 10, 2022 | Press Releases

The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a targeted disease.JUPITER, Fla., Feb. 10, 2022 (GLOBE NEWSWIRE) —...

Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

by dyadic | Feb 7, 2022 | Press Releases

JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein...

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

by dyadic | Jan 20, 2022 | Press Releases

JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...

Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan

by dyadic | Dec 22, 2021 | Press Releases

JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...

Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

by dyadic | Dec 17, 2021 | Press Releases

JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving,...